Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
The US Government AS Represented By The Department Of Veterans Affairs has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner and 1 distinct art unit. The prosecution activity is currently limited to this single matter. This concentration means that the outcome of the government's active patent efforts depends on the findings of a specific administrative group. Such a narrow focus allows the applicant to dedicate resources to a specific technical dialogue. The alignment of the technical subject matter within the specified group suggests a focused patenting strategy for the biotechnology technology.
ELLY GERALD STOICA is the busiest examiner for the portfolio, managing 1 pending office action. Since there is only 1 distinct examiner, this person is responsible for all active prosecution. The 1 distinct art unit shows the biotechnology technology is being reviewed by a single specialized group. For the applicant, this suggests a focused prosecution environment where consistency in examiner communication is paramount. The limited scope of the current activity simplifies the management of the portfolio. This examiner handles the total active matters for the firm, ensuring that all feedback is filtered through a specific professional perspective.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STOICA, ELLY GERALD | 1 | 66.8% | +22.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18460277 | OSTEOPONTIN MONOCLONAL ANTIBODIES FOR CANCER AND OSTEOPOROSIS IMMUNOTHERAPY | STOICA, ELLY GERALD | — |
| Art Unit | Apps |
|---|---|
| 1647 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18460277 | OSTEOPONTIN MONOCLONAL ANTIBODIES FOR CANCER AND OSTEOPOROSIS IMMUNOTHERAPY | STOICA, ELLY GERALD | 1647 | §112 | Non-Final OA | — | Pending | Sep 01, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialThe US Government AS Represented By The Department Of Veterans Affairs has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Elly Gerald Stoica has the most, with 1 of The US Government AS Represented By The Department Of Veterans Affairs's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.